🇪🇺 Chronic- PF-06480605 150 mg SC Q4W in European Union

Chronic- PF-06480605 150 mg SC Q4W (chronic-pf-06480605-150-mg-sc-q4w) regulatory status in European Union.

Marketing authorisation

EMA

  • Status: approved

Chronic- PF-06480605 150 mg SC Q4W in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Immunology approved in European Union

Frequently asked questions

Is Chronic- PF-06480605 150 mg SC Q4W approved in European Union?

Yes. EMA has authorised it.

Who is the marketing authorisation holder for Chronic- PF-06480605 150 mg SC Q4W in European Union?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.